Optimizing Cardiorenal Prognosis with GLP-1, SGLT2 Combination
The combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists may offer notable benefits for optimizing cardiovascular and renal outcomes in patients with diabetes, according to findings from a collaborative meta-analysis of trials from the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (SMART-C). A total of 12 SMART-C trials encompassing …